Ownership and insider activity for Mustang Bio, Inc. (MBIO): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relap...
Price
| Price | $0.50 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-04-24 | Litchman Manuel MD | F-InKind | 19 | $14 |
| 2026-01-02 | Fortress Biotech, Inc. | A-Award | 278,385 | |
| 2025-12-30 | Herskowitz Neil | S-Sale | 247 | $238 |
| 2025-12-30 | Chill Adam J. | S-Sale | 4 | $4 |
| 2025-12-30 | Jin David | P-Purchase | 247 | $238 |
| 2025-09-29 | Fortress Biotech, Inc. | A-Award | 59,334 | |
| 2025-04-24 | Litchman Manuel MD | F-InKind | 27 | $33 |
| 2025-03-31 | Fortress Biotech, Inc. | A-Award | 67,806 | |
| 2024-12-31 | Fortress Biotech, Inc. | |||
| 2024-10-23 | Jin David |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $27.5M | $35.0M | $16.5M | $61.4M | $97.8M | $109.6M | $75.7M | $6.2M | $6.8M | $17.3M |
| Short-term Investments | 0 | $26.0M | $17.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | $106000 | $37000 | $19000 | $15000 | $50000 | 0 | $3.9M | $402000 | $217000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $27.5M | $61.4M | $35.1M | $63.1M | $99.5M | $111.7M | $78.9M | $11.3M | $8.6M | $17.6M |
| Property, Plant & Equipment | 0 | $1.4M | $6.9M | $9.1M | $9.1M | $12.1M | $12.3M | $4.8M | $452000 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $27.5M | $63.5M | $42.8M | $73.4M | $109.9M | $125.2M | $92.4M | $17.7M | $9.3M | $17.6M |
| Accounts Payable | $683000 | $3.5M | $1.4M | $1.9M | $3.5M | $3.5M | $6.8M | $6.3M | $7.5M | $3.5M |
| Short-term Debt | $320000 | 0 | 0 | $1.2M | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $3.2M | $3.6M | $5.6M | $7.8M | $9.5M | $10.8M | $15.1M | $15.4M | $12.6M | $7.9M |
| Long-term Debt | 0 | 0 | 0 | $12.2M | 0 | 0 | $27.4M | 0 | 0 | 0 |
| Total Liabilities | $3.2M | $3.7M | $6.4M | $21.8M | $11.5M | $12.8M | $46.1M | $17.6M | $13.2M | $8.1M |
| Retained Earnings | -$17.1M | -$48.4M | -$79.1M | -$125.5M | -$185.5M | -$251.8M | -$329.4M | -$381.0M | -$396.7M | -$398.6M |
| Total Equity | $24.3M | $59.8M | $36.4M | $51.7M | $98.4M | $112.4M | $46.3M | $123000 | -$3.9M | $9.5M |
| Total Debt | $320000 | 0 | 0 | $15.5M | $2.2M | $2.0M | $31.4M | $2.5M | $878000 | 0 |
| Net Debt | -$27.2M | -$61.0M | -$34.1M | -$45.9M | -$95.6M | -$107.6M | -$44.3M | -$3.7M | -$6.0M | -$17.3M |
| Working Capital | $24.3M | $57.8M | $29.5M | $55.3M | $90.0M | $100.9M | $63.7M | -$4.0M | -$4.0M | $9.7M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 1.97 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -31.16 |
Profitability
| Return on Equity | -34.23% |
| Return on Invested Capital | -45.77% |
| Return on Assets | -19.43% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABP · ACXP · BOLT · DWTX · EVGN · IMRN · LYRA
Explore sector: Healthcare · Biotechnology
More sections of MBIO: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks